⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL91546 | 1.00 | — | — | |
| SCHEMBL321509 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL331264 | 0.97 | — | — | |
| Bromide SCHEMBL6581171 | 0.97 | — | — | |
| Ammonia Solution, Strong SCHEMBL22117616 | 0.97 | — | — | |
| Bromide SCHEMBL6581168 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL331433 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL492735 | 0.97 | — | — | |
| SCHEMBL118935 | 0.84 | — | — | |
| SCHEMBL4467686 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 581 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388543-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-12-25 | — | — | US | claimed |
| EP-4532014-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | Cerevance, Inc. (US) | 2025-04-09 | — | — | EP | claimed |
| WO-2023227867-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | Cerevance, Inc. (US) | 2023-11-30 | — | — | WO | claimed |
| US-20220267320-A1 | 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-PYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2022-08-25 | — | — | US | claimed |
| EP-1465864-B1 | INHIBITORS OF FACTOR XA AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE | WARNER LAMBERT CO (US) | 2006-03-15 | — | — | EP | claimed |
| EP-4027995-B1 | HPK1 ANTAGONISTS AND USES THEREOF | NIMBUS SATURN INC (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4029868-B1 | MCL-1 INHIBITORS | GILEAD SCIENCES INC (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-4739684-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | Janssen Pharmaceutica NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| WO-2026087909-A1 | COMPOUNDS FOR USE AS NEUROPROTECTIVE AGENTS AND/OR IN INHIBITING FORMATION OF ALPHA-SYNUCLEIN AGGREGATES | AC IMMUNE SA (CH) | 2026-04-30 | — | — | WO | disclosed |
| US-20260116881-A1 | KIF MODULATOR COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260116868-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260109697-A1 | 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-PYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2026-04-23 | — | — | US | disclosed |
| EP-1303272-A2 | BENZOTHIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-23 | — | — | EP | disclosed |
| US-6521754-B2 | Such as N-4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-methyl-isoni cotinamide | HOFFMAN-LA ROCHE INC. | 2003-02-18 | — | — | US | disclosed |
| US-20020045615-A1 | Benzothiazole derivatives with activity as adenosine receptor ligands | F.HOFFMANN-LA ROCHE AG (CH) | 2002-04-18 | — | — | US | disclosed |
| WO-2001097786-A2 | BENZOTHIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-12-27 | — | — | WO | disclosed |
| US-5082842-A | Sedatives | HOFFMANN-LA ROCHE INC. (US) | 1992-01-21 | — | — | US | disclosed |
| US-4889854-A | MUSCLE RELAXANT, SEDATIVE-HYPNOTIC, ANXIOLYTIC AND-OR ANTICONVULSANT ACTIVITY | HOFFMAN-LA ROCHE INC. (US) | 1989-12-26 | — | — | US | disclosed |
| CN-88103535-A | Tricyclic pyridine ketone derivatives and preparation method thereof | — | 1988-12-28 | — | — | CN | disclosed |
| EP-0294599-A2 | Tricyclic pyridone derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1988-12-14 | — | — | EP | disclosed |